Is visual acuity non‐inferior in full‐thickness macular holes treated with ocriplasmin?

Alberti, Mark; Cour, Morten la

doi:10.1111/aos.12856

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Postupak intravitrealne injekcije mnogo je jednostavniji nego vitrektomija, ali su rezultati glede zatvaranja rupture kao i poboljšanja vidne oštrine u literaturi različiti. U pojedinim radovima navodi se zatvaranje rupture uz upotrebu ocriplazmina u preko 40 % slučajeva, a u drugim bolji uspjeh vitrektomije 52,53 . Ne treba zaboraviti niti financijski efekt jer je terapija Ocriplasminom skuplja od vitrektomije.…”

Section: Enzimatska Viteolizaunclassified

Mikrokirurško liječenje rupture žute pjege

Kovačević

Čaljkušić-Mance

2019

Med. Flum. (Online)

View full text Add to dashboard Cite

Ruptura žute pjege poremećaj je koji zahvaća najdelikatnije strukture centralne mrežnice. Neliječena uglavnom dovodi do značajnog gubitka centralne vidne oštrine. Mikrokirurško liječenje rupture žute pjege prvi put se spominje 1991. godine u radovima Kelly i Wendela. Od tih relativno jednostavnih početaka uz upotrebu klasičnih vitrektoma velikog promjera i upotrebe zraka kao tamponade na kraju operacije do razvoja bešavnih mikroincizijskih tehnologija prošlo je više od 20 godina. Uvođenjem ljuštenja membrane limitans interne uz pomoć posebnih vitalnih boja i novih vrsta tamponada poboljšao se anatomski i funkcionalni uspjeh ovih operacija. Upotrebom optičke koherentne tomografije omogućena je bolja analiza vitreoretinalnih promjena, kao i praćenje postoperativnih promjena u području žute pjege. Nove metode u liječenju kompliciranih ruptura žute pjege kao što su formiranje inverznog poklopca od tkiva membrane limitans interne, farmakološka vitreoliza, transplantacija retine te novi oblici konzervativnog liječenja kod početnih ruptura žute pjege daju nadu da sve mogućnosti liječenja ove bolesti nisu iscrpljene.

show abstract

Section: Enzimatska Viteolizaunclassified

Mikrokirurško liječenje rupture žute pjege

Kovačević

Čaljkušić-Mance

2019

Med. Flum. (Online)

View full text Add to dashboard Cite

show abstract

“…The percentage falls to 4-16% if a size of less than 250 μm is used [12,13], where the hole closure rate with OCP approximately doubles from 25 to 50% [2,5]. Another specific concern is that OCP can increase the size of macular holes in those patients unsuccessfully treated [3], which may affect the visual result after subsequent 'rescue' surgery, although these concerns have not been proven [14].…”

mentioning

confidence: 99%

Cochrane Corner: Ocriplasmin—why isn’t it being used more?

Grinton

Steel

2019

Eye

View full text Add to dashboard Cite

Ocriplasmin: who is the best candidate?

Ponce¹,

Stevenson²,

Gelman³

et al. 2016

OPTH

View full text Add to dashboard Cite

Enzymatic vitreolysis is currently the focus of attention around the world for treating vitreomacular traction and full-thickness macular hole. Induction of posterior vitreous detachment is an active area of developmental clinical and basic research. Despite exerting an incompletely elucidated physiological effect, ocriplasmin (also known as microplasmin) has been recognized to serve as a well-tolerated intravitreal injection for the treatment of vitreomacular traction and full-thickness macular hole. There are several unexplored areas of intervention where enzymatic vitreolysis could potentially be used (ie, diabetic macular edema). Recent promising studies have included combinations of enzymatic approaches and new synthetic molecules that induce complete posterior vitreous detachment as well as antiangiogenesis. Although no guidelines have been proposed for the use of ocriplasmin, this review attempts to aid physicians in answering the most important question, “Who is the best candidate?”

show abstract

Is visual acuity non‐inferior in full‐thickness macular holes treated with ocriplasmin?

Cited by 3 publications

References 6 publications

Mikrokirurško liječenje rupture žute pjege

Mikrokirurško liječenje rupture žute pjege

Cochrane Corner: Ocriplasmin—why isn’t it being used more?

Ocriplasmin: who is the best candidate?

Contact Info

Product

Resources

About